Physician Wealth Advisors Inc. purchased a new position in shares of Everus (NYSE:ECG – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 1,125 shares of the company’s stock, valued at approximately $74,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. purchased a new stake in Everus in the 4th quarter worth approximately $16,241,000. Yousif Capital Management LLC purchased a new stake in shares of Everus during the fourth quarter worth $1,326,000. Principal Securities Inc. acquired a new stake in Everus during the fourth quarter valued at $27,000. Cascade Investment Advisors Inc. purchased a new position in Everus in the fourth quarter valued at about $1,272,000. Finally, Register Financial Advisors LLC acquired a new position in Everus in the 4th quarter worth about $3,167,000.
Insider Transactions at Everus
In other news, Director Edward A. Ryan acquired 1,400 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The shares were bought at an average price of $38.02 per share, with a total value of $53,228.00. Following the acquisition, the director now owns 14,928 shares of the company’s stock, valued at $567,562.56. This trade represents a 10.35 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rocca Michael Della acquired 1,050 shares of the stock in a transaction dated Tuesday, February 18th. The shares were purchased at an average price of $47.56 per share, for a total transaction of $49,938.00. Following the completion of the transaction, the director now owns 2,027 shares of the company’s stock, valued at $96,404.12. This trade represents a 107.47 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 3,750 shares of company stock worth $153,853.
Everus Trading Up 3.3 %
Everus (NYSE:ECG – Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported $0.67 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.06). As a group, research analysts predict that Everus will post 2.49 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the company. Oppenheimer lifted their price target on Everus from $70.00 to $80.00 and gave the company an “outperform” rating in a report on Tuesday, January 7th. Stifel Nicolaus reduced their target price on shares of Everus from $85.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Wolfe Research began coverage on Everus in a research report on Tuesday, December 3rd. They issued a “peer perform” rating for the company.
Check Out Our Latest Stock Report on ECG
Everus Company Profile
Everus Construction Group is providing a full spectrum of construction services through its electrical and mechanical and transmission and distribution specialty contracting services principally in United States. Its specialty contracting services are provided to utility, transportation, commercial, industrial, institutional, renewable and other customers.
Featured Stories
- Five stocks we like better than Everus
- Insider Trading – What You Need to Know
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- MarketBeat Week in Review – 03/24 – 03/28
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Want to see what other hedge funds are holding ECG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Everus (NYSE:ECG – Free Report).
Receive News & Ratings for Everus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Everus and related companies with MarketBeat.com's FREE daily email newsletter.